Some of these ACE2 inhibitors have been shown to increase cardiac hypertrophy and fibrosis (Trask et al., 2010) while ACE2 activators have been shown to have significant anti-hypertensive action and be effective in the reversal of cardiac and renal fibrosis (Varagic et al., 2014). This evidence concerns the gene ACE2 and renal fibrosis.